SEC Form 4 · accession 0001104659-16-094738
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur S Kirsch
Director
Period of report
Feb 5, 2016
Accepted (ET)
Feb 8, 2016 · 6:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 5, 2016 | M | 6,107 | $5.97 | A | 64,719 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $5.97 | Feb 5, 2016 | M | 6,107 | D | Jun 10, 2011 | — | Common Stock | 6,107 | 0 | D |
Explanation of responses
- F1Pursuant to a merger agreement entered into by the registrant, the expiration date of this stock option grant was accelerated to February 5, 2016.